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Abstract
Pituitary adenomas (PA) represent the largest group of intracranial neoplasms and 
yet the molecular mechanisms driving this disease remain largely unknown. The aim 
of this study was to use a high-throughput screening method to identify molecular 
pathways that may be playing a significant and consistent role in PA. RNA profiling 
using microarrays on eight local PAs identified the aryl hydrocarbon receptor (AHR) 
signalling pathway as a key canonical pathway downregulated in all PA types. This was 
confirmed by real-time PCR in 31 tumours. The AHR has been shown to regulate cell 
cycle progression in various cell types; however, its role in pituitary tissue has never been 
investigated. In order to validate the role of AHR in PA behaviour, further functional 
studies were undertaken. Over-expression of AHR in GH3 cells revealed a tumour 
suppressor potential independent of exogenous ligand activation by benzo α-pyrene 
(BαP). Cell cycle analysis and quantitative PCR of cell cycle regulator genes revealed that 
both unstimulated and BαP-stimulated AHR reduced E2F-driven transcription and altered 
expression of cell cycle regulator genes, thus increasing the percentage of cells in G0/G1 
phase and slowing the proliferation rate of GH3 cells. Co-immunoprecipitation confirmed 
the interaction between AHR and retinoblastoma (Rb1) protein supporting this as a 
functional mechanism for the observed reduction. Endogenous Ahr reduction using 
silencing RNA confirmed the tumour suppressive function of the Ahr. These data support 
a mechanistic pathway for the putative tumour suppressive role of AHR specifically in PA, 
possibly through its role as a cell cycle co-regulator, even in the absence of exogenous 
ligands.
Introduction
Pituitary adenomas (PA) represent the commonest cranial 
neoplasms and vary in size, type and aggressiveness. 
Clinically relevant PAs result in symptoms due to 
hormonal hypersecretion, intracranial mass effects 
or secondary hypopituitarism and locally occur with 
an average prevalence of approximately 76/100,000 
(Gruppetta  et  al. 2013). The vast majority of PAs are 
sporadic in origin with only a small number of significant 
genetic mutations identified in relatively rare familial 
cases and endocrine syndromes. The heterogenous nature 
of PAs poses challenges in the elucidation of the molecular 
mechanisms driving their formation and progression 
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(Asa et al. 2017). This contrasts significantly with current 
knowledge in relation to malignant tumours.
Certain key pathways have already garnered a 
great deal of attention, including the cAMP secondary 
messenger signalling pathway, the Wnt signalling pathway 
and the pI3K/Akt signalling pathways (Chambers  et  al. 
2013, Formosa & Vassallo 2014, Monsalves  et  al. 2014, 
Peverelli  et  al. 2014). However, even collectively, these 
molecular pathways do not cater for the entirety of the 
mechanisms that are responsible for the development 
and/or progression of PAs, making our understanding 
of the disease as yet limited. Several studies using high-
throughput techniques including microarray studies 
and large-scale sequencing have identified a number of 
interesting pathways (Moreno  et  al. 2005, Morris  et  al. 
2005, Evans  et  al. 2008, Jiang  et  al. 2010, Newey  et  al. 
2013, Valimaki  et  al. 2015). In an attempt to uncover 
more molecular mechanisms driving Pas, we screened 
RNA profiles expressions of local tumours to uncover 
common altered pathways among a heterogeneous set of 
PAs. A consistently altered pathway observed implicated 
xenobiotic signalling.
The AHR is a ligand-activated transcription factor 
containing the basic helix-loop-helix (bHLH)/PAS domain 
mediating the response to a variety of environmental 
toxins (Burbach et al. 1992). Unliganded AHR is maintained 
in the cytoplasm bound to a chaperone complex together 
with HSP90, p23 protein and the aryl hydrocarbon 
receptor-interacting protein (AIP). Upon ligand binding, 
the AHR disengages and translocates to the nucleus where 
it binds to the aryl hydrocarbon nuclear translocator 
(ARNT). Together with a number of co-activators and 
co-repressors, AHR forms a transcription complex on 
consensus DNA sequences called xenobiotic response 
elements (XRE) located upstream of the promoters of AHR 
target genes such as the cytochrome P450 genes (CYP1A1 
and CYP1B1) (Davarinos & Pollenz 1999, Whitlock 1999). 
AHR signalling has been shown to be functionally active 
in pituitary cells, which respond rapidly to exogenous 
ligands (Huang et al. 2002).
The AHR is constitutively active and plays a 
significant role in cell homeostasis in a number 
of organs in the absence of any exogenous ligand 
(Singh et al. 1996, Crawford et al. 1997, Chang & Puga 
1998, Murray  et  al. 2005). AHR knockout mice have 
decreased liver size, decreased body weight and reduced 
reproductive potential. AHR also directly effects cell cycle 
progression and differentiation in the absence of any 
exogenous ligand in several cell lineages (Bauman et al. 
1995, Ma & Whitlock 1996, Levine-Fridman et al. 2004, 
Marlowe et al. 2004).
There are conflicting reports postulating both tumour 
suppressive and oncogenic roles for AHR depending on 
cell and context specificity. Most data so far regarding 
the involvement of AHR in cancer have been obtained 
from malignant forms of the disease indicating both 
a cancer promoting role for AHR (Andersson  et  al. 
2002, Moennikes  et  al. 2004, Feng  et  al. 2013) or a 
tumour suppressive role in cancer (Schmidt  et  al. 1996, 
Gonzales et al. 1998, Ito et al. 2004, Mulero-Navarro et al. 
2006, Fritz et al. 2009, Fan et al. 2010, Spink et al. 2013). 
However, no direct evidence has been found as yet linking 
the functional role of AHR in pituitary tumour formation 
or behaviour. Investigation in PAs has focused mainly on 
the role of AHR in relation to the AIP. Germline mutations 
of AIP have been found to increase susceptibility to 
familial cases of PAs (Vierimaa  et  al. 2000). Lecoq  et  al. 
(2016) showed that AIP mutations do not alter AHR 
expression but can downregulate the expression of 
AHR target genes, thereby effecting AHR transcriptional 
activity. Reports documenting detailed analysis of this 
and possibly other mechanistic pathways involved in 
pituitary tumourigenesis are to date lacking.
The aim of our study was therefore to identify 
novel pathways involved in pituitary tumour formation 
by microarray analysis of PAs from Maltese patients 
compared to a pooled control sample and subsequently 
to functionally analyse such pathways using in vitro 
models.
Materials and methods
Tumour collection and characterization
Tumours were collected from 31 patients undergoing 
trans-sphenoidal surgery at Mater Dei Hospital, Malta (19 
non-functioning PA, 8 GH-secreting PA, 2 PRL-secreting 
PA, 2 ACTH-secreting PA). Informed consent was obtained 
from all patients. Samples were collected in RNAlater (Life 
Technologies) and stored at −20°C until processing. Data 
on the clinical and biochemical hormone profiles and 
as well as standard immunohistochemistry for anterior 
pituitary hormones were used for characterization of the 
adenomas. Patients’ details are summarized in Table  1. 
Control human pituitary mRNA was obtained from 
Clontech and contained pooled RNA from 39 male/
female Caucasians aged 20–60 years.
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RNA extraction and quantitative PCR (qPCR)
Pituitary samples were removed from RNAlater and 
placed at −80°C overnight. Cells were disrupted using a 
mortar and pestle and homogenized using Qiashredder 
(Qiagen). RNA was extracted using a standard protocol 
from RNeasy Mini extraction kit (Qiagen). RNA 
extraction from GH3 cells was carried out using the 
RNeasy Mini kit 48 h after transfection with expression 
vectors and 24 h after treatment with activating ligand 
in 6-well plates.
cDNA synthesis for qPCR was carried out with 
1 μg of RNA and random hexamers using the GoScript 
Reverse transcription system (Promega). Details of qPCR 
conditions and list of primers used can be found in the 
Supplementary section (see section on supplementary 
data given at the end of this article). qPCR on RNA from 
31 tumours samples collected locally was used to verify 
results obtained by microarray. Subsequently, qPCR on 
GH3 cells was carried out to study the effects of AHR over-
expression and knockdown on target gene transcription.
Microarray and data analysis
mRNA profiling of the eight tumour samples and control 
pituitary RNA was carried out using the HuGene 1.0 ST 
Array (Affymetrix) at Erasmus Medical Centre, Erasmus 
University, Rotterdam, the Netherlands. Data analysis was 
carried out using the GeneSpring 11.0 software (Agilent 
Technologies, with comparison between all tumours vs 
controls, non-functional tumours vs controls, functional 
tumours vs controls and functional vs non-functional 
tumours). A two-fold difference was used as a cut-off for 
significant results.
Data were analysed through the use of QIAGEN’s 
ingenuity pathway analysis (IPA, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). The most significant 
pathways were identified based on right-tailed Fisher’s 
exact test.
Cell culture and in vitro analysis
In vitro analysis was carried out to analyse the effect of 
AHR signalling on GH3 rat sommatolactotroph pituitary 
cells. GH3 cells were cultured in DMEM with 10% FBS 
and 1% antibiotics (Sigma). To study the influence of 
AHR signalling, GH3 cells were transfected with AHR 
expression vector in pcDNA3, generously donated by 
Prof. Anette Duensing, University of Pittsburgh Cancer 
Institute, Pittsburgh, USA. Activation of AHR was 
achieved using benzo (alpha) pyrene (BαP) (Sigma) at 
concentrations varying from 0.1 µM to 10 µM dissolved in 
DMSO and diluted in water. Knockdown of endogenous 
Ahr was achieved using commercial siRNAs (Dharmacon) 
and optimized with Lipofectamine RNAiMAX 
transfection agent.
Proliferation assays
GH3 cells were seeded in 96-well plates at 10,000 cells 
per well. After 24 h, cells were transfected with varying 
quantities of AHR expression vector using Fugene HD 
(Promega) transfection reagent at a 3:1 (Fugene:DNA) 
ratio according to manufacturer’s instructions. For 
knockdown experiments, GH3 cells were transfected with 
0.5, 1 or 2 pmol of rat Ahr siRNA or control (negative) 
siRNA (Dharmacon, USA) using Lipofectamine RNAiMAX 
(Invitrogen) using the manufacturer’s instructions. 
Cells were then left in the incubator for 24–72 h post 
transfection. MTT readings were taken at 24-h time 
intervals up to 96 h post transfection using the Mithras LB 
940 (Berthold Technologies, Bad Wildbad, Germany). Five 
repeats per treatment were used and experiments were 
carried out in triplicate.
Luciferase reporter gene activity
Dual luciferase assays reporter assays were used to assess 
the activity of AHR in GH3 cells. The transcriptional 
Table 1 Patient characteristics of tumour RNA used for microarray analysis.
Patient Sex Age at diagnosis Tumour type Tumour diameter (mm) Treatment Invasive
1 F 62 TSH/prolactin secreting 24 Octreotide No
2 F 40 Acromegaly 20  Yes
3 M 52 Acromegaly 10  No
4 M 60 NFPA 20  No
5 F 79 NFPA NA  Yes
6 M 47 NFPA 25 Bromocriptine Yes
7 M 48 NFPA 36  Yes
8 F 54 NFPA 13  Yes
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activity on the xenobiotic response element (XRE) was 
assessed using an XRE-driven reporter expression vector 
containing 3 copies of the Cyp1a1 XRE kindly donated 
by Prof. Albert Braeuning (University of Tuebingen, 
Germany). The effect of AHR on E2F transcriptional 
activity was analysed using an E2F-driven reporter plasmid 
containing three E2F-binding sites kindly donated by 
Prof. Alvaro Puga (University of Cincinnati, OH, USA).
For reporter gene activity, GH3 cells were seeded 
in 2F4-well plates at 50,000 cells per well. After 24 h, 
transfections with expression vectors and/or silencing RNA 
were carried out in accordance with the manufacturer’s 
instructions. Transfection mixtures contained 0.4 μg AHR 
vector or empty vector (pcDNA3 only), 0.4 μg reporter 
plasmid (XRE or E2F reporter gene) and 0.01 µg pRL-TK 
(renilla expression vector) per well. For knockdown 
experiments, 5 pmol of Ahr siRNA or control siRNA 
replaced the AHR/EV expression vectors in the transfection 
mixtures and RNAiMAX reagent was used instead of 
FuGENE. 24 h after transfection, BαP was also added at 
the required concentration. After another 24 h, cells were 
lysed with 100 µL passive lysis buffer and dual luciferase 
activity was read using the Dual Luciferase Reporter Assay 
(Promega) in the TD-20/20 Luminometer (Turner Designs, 
San Jose, CA, USA). Each treatment was carried out in 
triplicate, and experiments were replicated 3 times.
Co-immunoprecipitation and Western blot
Co-immunoprecipitation (co-IP) was carried out on GH3 
cells treated with either vehicle (DMSO) or 1 μM BαP for 
1 h prior to lysis in whole cell lysis buffer. Co-IP was also 
carried out on GH3 cells transfected with AHR expression 
vector or Ahr siRNA and lysates where taken 48 h after 
transfection. Co-IP was carried out using the Universal 
Magnetic Co-IP kit (Active Motif, Carlsbad, CA, USA) 
using the manufacturer’s instructions. 500 µg of whole 
cell lysate was incubated with 2 µg of Ahr antibody (RPT1, 
Novus Biologicals, Littleton, CO, USA) for 4 h on ice prior 
to precipitation with magnetic beads. 20 µg of eluted 
protein was then analysed by standard Western blot for 
the presence of the precipitated endogenous Ahr (RPT1 
antibody) and the co-immunoprecipitated Rb protein 
using Rb1 antibody (1F8, Novus Biologicals) for detection. 
Detection was carried out using anti-mouse secondary 
antibody (IRDye 800CW, Li-Cor Biotechnology, Lincoln, 
NE, USA) and read on the Odyssey Imaging System 
(Li-Cor Biotechnology). β-Actin antibody (AC-15, Novus 
Biologicals) was used to verify the success and specificity 
of co-immunoprecipitation. Similar protocol was used to 
verify the success of transfection with AHR vector and 
knockdown of endogenous Ahr with siRNA.
Cell cycle analysis
Cell cycle analysis was carried out on GH3 cells in 24-well 
plates under the same experimental conditions used for 
the luciferase reporter assays except that only one vector 
or siRNA was transfected at any experimental condition. 
Prior to addition of BαP, the medium was replaced with 
fresh DMEM with no serum or antibiotics, and after 6 h, 
serum was added to synchronize the cells. After 24 h, cells 
were fixed in cold 70% ethanol overnight, washed with 
PBS and re-suspended in 500 μL of RNase solution (Sigma) 
and left for 30 min at 37°C. The cells were stained with 
200 μL 50 μg/mL propidium iodide (Sigma) prior to flow 
cytometry, which was carried out using FACSCalibur (BD 
Biosciences, USA). Data were analysed using CellQuest 
Pro (BD Biosciences). Experiments were carried out in 
triplicate and replicated three times.
Statistics
All data were analysed using SPSS Statistics, version 17 
(IBM). Kolmogorov–Smirnov test was carried out on all 
the raw data to determine the normal distribution of the 
data. For the proliferation assays, ANOVA analysis was 
used, while for the luciferase assays, real-time PCR and 
cell cycle analysis, pairwise t-tests (for parametric data) 
or Wilcoxon t-test (for non-parametric data) were used. 
Statistical significance was set at the 5% confidence level.
Results
Microarray analysis and confirmation by 
quantitative PCR
Microarray analysis carried out on 8 tumours and a pooled 
control RNA revealed significant differences. Comparison 
by gender and tumour invasiveness revealed little or 
no difference in mRNA expression profiles of tumours. 
Comparison of controls vs all tumours revealed a total of 
1409 differently expressed genes, of which 842 genes were 
downregulated and 567 were upregulated. Expression 
profiles of the different tumour types were also compared 
to each other and to controls separately. Additionally, 
one tumour (patient 8) characterized biochemically and 
immunohistochemically as a non-functional adenoma had 
a RNA expression profile resembling a functional tumour 
when unsupervised clustering was carried out as shown 
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below. Upon further patient follow-up and biochemical 
investigation, the patient was indeed found to have a 
functional adenoma. In subsequent analyses, this tumour 
was therefore grouped with the functional adenomas.
qPCR was subsequently carried out on 31 samples 
including the 8 patients used for microarray analysis. A 
number of genes found to be deregulated by microarray 
analysis and related to the AHR signalling pathway 
were selected. qPCR confirmed the findings observed 
by microarray analysis (Fig.  1). AHR expression levels 
per se were not significantly altered, while xenobiotic 
target genes identified by microarray, were found to be 
significantly reduced in the 31 tumours analysed, thereby 
confirming the findings of the microarray and pathway 
analyses regarding the downregulation of AHR signalling.
Ingenuity pathway analysis (IPA)
The IPA software was used to analyse the list of de-regulated 
gene expressions and to identify pathways and cellular 
mechanisms that are altered in PAs as reflected by their 
expression profiles. IPA uses a vast database of gene 
functions and interactions based on data from human, rat 
and mouse studies.
Among the many pathways identified by the software, 
one of the most prominent and recurring pathways 
identified during each analysis was the aryl hydrocarbon 
receptor (AHR) signalling pathway. This pathway 
was significantly altered in all comparisons, whether 
comparing all tumours to control or specific tumour 
types alone to controls, with a P value of less than 0.001 
in all analyses. Supplementary Figure  1 indicates part 
of the AHR signalling pathway, which was found to be 
de-regulated in all PA vs controls. Although the AHR itself 
was not found to be significantly differentially expressed, 
the cut-off level of a two-fold difference implies that small 
changes might be missed. However, several downstream 
AHR transcriptional targets, such as CYP1B1, ALDH and 
GST genes were found to be significantly reduced with 
more than two-fold differences observed between tumours 
and controls.
In vitro analysis of AHR activity in GH3 cells
Given the downregulation of AHR signalling demonstrated 
by microarray and IPA, in vitro analyses using the 
established GH3 cell line were performed to investigate 
the functional role of the AHR in PA. Proliferation 
analysis was carried out using MTT assays with BαP, a 
potent ligand of the AHR, as an activator. Endogenous 
Ahr activation by BαP alone did not alter cell proliferation 
significantly except at a concentration of 10 μM after 72 h 
of treatment, an effect likely to be due to toxicity of the 
agent as observed microscopically (Fig. 2A).
In order to further investigate the role of AHR in 
mediating cell proliferation and function, it was decided 
to analyse the effect of over-expressing AHR in GH3 cells. 
As observed in Fig. 2B, increasing AHR resulted in a dose-
dependent decrease in cell proliferation with a significant 
decrease observed at 0.1 μg of transfected AHR vector 
when compared to the same dose of empty vector at 
each time point and in the absence of exogenous ligand. 
The combination of both AHR overexpression and BαP 
ligand was also tested (Fig. 2C). At all time points, GH3 
cells overexpressing AHR without BαP treatment all had 
significantly lower proliferation when compared to cells 
treated with empty vector alone. Addition of BαP only 
resulted in a significant reduction in proliferation when 
compared to similarly treated cells with empty vector, 
at very low concentrations of 10 nM and only at two 
time points. Further increase in BαP concentration did 
not result in any significant difference in proliferation 
between cells overexpressing AHR or empty vector.
In order to confirm our findings, knockdown of 
endogenous Ahr using silencing RNA was also carried 
out using three concentrations of the siRNAs and at three 
different time points. As observed in Fig. 2D, GH3 cells 
with reduced endogenous Ahr expression had higher 
proliferative rates than their control counterparts at 
Figure 1
qPCR of target genes to confirm data obtained by microarray analysis. 
Genes with de-regulated expression as compared to normal pituitary 
were analyzed using GAPDH and EMC7 as housekeeping genes. (CYP1B1, 
cytochrome P450 1B1, GST; gluthionine S-transferase, ALDH3A1; aldehyde 
dehydrogenase family 3, A1, JUN; Jun oncogene, NFPA; non-functioning 
PA, FPA; functional PA, GH-S; growth hormone secreting PA, PRL-S; 
prolactin-secreting PA, ACTH-S, adrenocorticotropic hormone-secreting 
PA). qPCR experiments were done in triplicate and error bars indicate 
standard error. (*P<0.05).
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all time points and concentrations, with significant 
differences observed at 1 pmol of siRNA transfected per 
well. Higher concentration of siRNA resulted in reduced 
proliferation probably due to the toxic effect of higher 
doses of the transfection reagent.
AHR signalling in GH3 cells
Since BαP treatment on GH3 cells and GH3 cell 
overexpressing human AHR had little effect on cell 
proliferation, we wanted to verify whether xenobiotic 
AHR signalling was indeed occurring within the GH3 
cells. Luciferase reporter assay using an XRE-driven 
luciferase gene showed a significant increase in luciferase 
activity only in the presence of BαP activating ligand 
and in a dose-dependent manner (Supplementary 
Fig. 2A). No activation was observed at 10 nM since this 
concentration is too low to achieve significant activation 
(De Waard et al. 2008) while 10 μM BαP proved too toxic 
to the cells. Knockdown of endogenous Ahr attenuated 
the XRE-driven luciferase activity, thereby showing the 
direct functional impact of Ahr and its activating ligand 
on XRE promoter activity.
Secondly, quantitative PCR was used to measure the 
expression levels of Ahr target genes in the GH3 cells to 
ascertain that the transfected AHR could functionally 
activate transcription in these cells. Real-time PCR of 
three Ahr target genes, Cyp1a1, Cyp1b1 and Aldh3a1, was 
carried out (Supplementary Fig. 2B). Treatment with BαP 
alone was able to significantly stimulate Aldh3a1 gene 
expression only while transfection with AHR expression 
vector and treatment with exogenous activator was able 
to significantly induce expression of all three target 
genes showing the functional ability of AHR to activate 
Figure 2
Proliferation (MTT) assays were carried out to study the role of AHR signaling on GH3 cell proliferation at different time points. (A) GH3 cells treated 
with BαP at different concentrations over three days. (B) GH3 cells transfected with increasing amounts of AHR/EV (pcDNA3) expression vectors and 
analyzed at three different time points from transfection. Insert shows increase in expression of transfected AHR with western blot using B-actin as 
loading control (C) GH3 cells transfected with AHR or EV plasmid and treated with BαP at different concentrations 24 hours after transfection and 
assayed at different time points post-transfection. (D) GH3 cells were transfected with Ahr or Control (Ctrl) siRNA at different concentrations and 
proliferation measurements taken at 3 time points. Insert shows a western blot reflecting the efficiency of Ahr silencing using siRNA. Experiments were 
done in repeats of 5 per treatment and each experiment was repeated at least three times. (*P< 0.05, error bars represent standard error).
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the transcription of target genes even in rat GH3 cells. 
Similarly, knockdown of endogenous Ahr once again 
attenuated this effect and rescue with human AHR by 
transfection was able to restore downstream Ahr target 
expression in response to ligand (Supplementary Fig. 2B).
AHR-Rb co-immunoprecipitation and effect on cell cycle 
regulators
Given the reported direct and indirect interaction of 
AHR with a number of cell cycle regulators such as Rb 
and CDNKs (Kolluri  et  al. 1999, Puga  et  al. 2000), we 
wished to investigate whether AHR overexpression 
and activation would have the same effects in pituitary 
cells as those reported in other tissues. The interaction 
between AHR and Rb proteins has been documented in 
a number of cell types resulting in prolonged activity of 
Rb and reduction in E2F transcriptional activity normally 
required for cell cycle progression (Feng  et  al. 2013). In 
order to verify whether this interaction was present in our 
cell line, co-immunoprecipitation of endogenous Ahr was 
carried out. As observed in Fig. 3A, isolation of Ahr from 
the cell lysate of GH3 cells also precipitated Rb protein 
with the addition of BαP ligand having little effect on the 
amount of Rb protein co-precipitated. Overexpression of 
AHR resulted in slightly increased Rb precipitation while 
silencing of endogenous Ahr reduced the amount of 
precipitated Rb considerably.
We therefore proceeded to analyse the effect of 
AHR on E2F-driven transcription using an E2F-luciferase 
reporter expression vector. Overexpression of AHR showed 
a marked decrease in E2F-driven luciferase expression in 
cells while Ahr silencing resulted in an increase in E2F-
driven luciferase activity (Fig. 3B). Treatment with BαP did 
not have any significant effect on E2F-driven transcription 
at any concentration, thus supporting the hypothesis 
that the reduction in E2F-driven luciferase was achieved 
through Ahr protein expression alterations without the 
need for an exogenous activating ligand in GH3 cells.
The expression of particular cell cycle regulators 
that are known to be affected by AHR was also analysed. 
Cdkns, cyclins and cdks were reported to be differentially 
expressed in vitro as a result of AHR signalling activity 
(Levine-Fridman  et  al. 2004, Marlowe  et  al. 2006, 
Pang  et  al. 2008, Tomblin & Salisbury 2014). Real-
time PCR for the specific genes is shown Fig. 3C below. 
Cyclin D1 (Ccnd1) expression was not affected while 
Cyclin E1 (Ccne1) expression was significantly reduced 
by overexpressed AHR treated with ligand. Cdkn1a 
(p21) gene expression was significantly overexpressed in 
Figure 3
Co-immunoprecipitation of Ahr and Rb1 in Gh3 cells and the effect of AHR over-expression and exogenous stimulation on cell cycle regulators in GH3 
cells. (A) Co-IP was carried out in GH3 cells and western blot with 20μg of cell lysate or precipitated proteins was run using anti-Rb1 and ant-Ahr 
antibodies on a negative control with lysate run through Ig beads with no antibody (Ctrl), the whole cell lysate prior to precipitation (input) and Co-IP 
using anti-AHR for pull down. Lane 1 of the co-IP represents untreated cells, lane 2 contains the precipitate from GH3 cells over-expression AHR, lane 3 
from GH3 cells treated with 1µM BαP prior to lysis and lane 4 with lysate from GH3 cells with knocked down Ahr protein. (B) GH3 cells were 
co-transfected with AHR or EV together with an E2F-driven luciferase reporter plasmid and treated with no BαP (-), 100nM or 1µM BαP for 24 hours prior 
to lysis and luciferase readings. For knock down experiments, GH3 cells were transfected with reporter plasmid and Ahr or control (Ctrl) siRNA) for 24 
hours prior to luciferase reading. (C) GH3 cells were transfected with either AHR/EV or Ahr siRNA and treated with 1μM BαP for 24 hours prior to lysis 
and RNA extraction. Experiments were repeated three times and luciferase studies were done in triplicate while qPCR readings were done in duplicate 
and repeated three times. (*P<0.05, **P< 0.01, error bars indicate standard error).
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GH3 cells overexpressing AHR only, and this effect was 
further amplified by addition of BαP activating ligand. 
Knockdown of Ahr by mRNA silencing only significantly 
reduced Cdkn1a expression, a reversal of the effect of AHR 
overexpression. In conclusion therefore, AHR activity in 
GH3 cells significantly altered the expression of at least 
two important inhibitors of cell cycle progression.
Cell cycle genes expression in PA
Expression in CDKs and CDKNs was also altered in the 
pituitary tumour RNA from the 31 patients. Microarray 
analysis revealed the CDKN2A and CDKN1A genes to be 
significantly repressed in all tumour types vs controls 
while the CDK2 gene was upregulated in the all tumours vs 
controls and CDK6 was also upregulated in GH-secreting 
tumours vs controls (data not shown). These results were 
tested by qPCR (Fig.  4) and gene expression of several 
other cell cycle regulators was also analysed. No significant 
differences in CDKN1B and CDK2, 6 gene expression 
(data not shown) was observed in the tumours vs control 
RNA. Cyclin E1 (CCNE1) expression was significantly 
higher in all tumour types vs controls while Cyclin D1 
(CCND1) gene expression was higher in all tumour types 
except prolactinomas and ACTH-secreting tumours 
when compared to control RNA. CDKN1A (p21) gene 
expression was significantly lower in non-functioning 
tumours vs controls while CDK1 expression was high in 
all tumour types but only reached statistical significance 
in GH-secreting tumours. Lack of statistical significance 
for the prolactinomas and ACTH-secreting tumours is 
likely due to the small number of samples available.
AHR effects cell cycle progression
AHR activity has been shown to affect the cell cycle both 
in the absence and presence of activating ligands in 
cells lines of mostly epithelial, hepatic or breast origin. 
Data from GH3 cells overexpressing AHR demonstrate 
that both stimulated and unstimulated AHR can reduce 
Figure 4
Gene expression analysis of specific cell cycle regulator genes in 31 
pituitary adenomas, divided by tumour type and shown as fold changes 
over control pituitary RNA. qPCR readings were done in duplicate and 
repeated three times. (*P<0.05, error bars indicate standard error).
Figure 5
Cell cycle analysis was carried out on GH3 cells 
transfected with AHR/EV or Ahr/Ctrl siRNA and 
treated with vehicle or BαP for 24 hours prior to 
fixation and flow cytometry. (A) Percentage of 
GH3 cells in G0/G1 phase in differently treated 
cells. Cell cycle analysis was done in triplicate and 
experiment was repeated three times using 
synchronized cells. (B) Cell Quest Pro software 
was used to gate the cell population and only 
gated cells were used for the final cell cycle 
analysis. Areas designated as belonging to G0/G1 
(M1), S phase (M2) and G2 phase were assigned as 
shown. (*P<0.05, error bars represent standard 
error).
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E2F transcriptional activity and expression of cell cycle 
regulators in GH3 cells. Therefore, the direct effect on cell 
cycle progression was further analysed using propidium 
iodide and flow cytometry. As observed in Fig. 5 below, 
GH3 cells overexpressing AHR had a significantly higher 
percentage of cells in G0/G1 phase when compared to cells 
transfected with an empty vector. Treatment with 100 nM 
and 1 μM exogenous BαP did not alter the percentage 
of cells in G0/G1 significantly. Conversely, GH3 cells 
with reduced expression of endogenous Ahr had lower 
percentage of cells in G0/G1 phase.
Discussion
The role of the AHR in carcinogenesis has been the subject of 
debate since it appears to be able to act both as an oncogene 
and a tumour suppressor in different cell types and 
contexts (Marlowe & Puga 2005). However, most cases of 
oncogenic AHR activity involve malignant forms of cancer, 
which differ significantly from pituitary tumour behaviour, 
which is benign in nature. Very few studies have looked at 
the impact of AHR signalling on PA. AHR expression was 
found to be altered in one study (Jaffrain-Rae et al. 2009) 
with reduced immunohistochemical expression of AHR in 
pituitary tumours as compared to normal controls. AHR 
was also found to be under-expressed in invasive adenomas 
and those tumours with demonstrated AIP mutations. 
Another study by the same group also revealed a significant 
negative correlation between AHR expression and pituitary 
tumour size and suprasellar extension indicating again 
that tumours with high AHR exhibited less aggressive 
behaviour, thereby indicating a possible growth advantage 
obtained by reducing AHR expression in tumours (Jaffrain-
Rae  et  al. 2013). Similarly, protein data mining by Zhan 
and Desiderio (2010) using IPA on several proteomic 
expression data identified the AHR signalling pathway 
as a significantly altered pathway in almost all of their 
analyses, with this pathway featuring repeatedly in the top 
10 significantly altered pathways although no indication 
was given whether the pathway was activated or repressed 
in PAs. Additionally, one microarray study carried out on 5 
prolactinoma samples identified members of the xenobiotic 
signalling pathway to be significantly downregulated but 
failed to elaborate further on these findings (Jiang  et  al. 
2010). Hence, evidence for a tumour-suppressive role in 
PA already existed, based on previous studies. This paper 
is the first to map out a mechanistic pathway for AHR in 
pituitary tumourigenesis using both in vivo material from 
human pituitary tumours and in vitro analysis.
In contrast to other studies involving AHR in cancer 
biology, this study was able to prove that AHR may act 
on the cell cycle even in the absence of an exogenous 
activating ligand, thereby suggesting a mechanism of 
action independent of its role as a xenobiotic receptor. In 
this study, BαP was used as an exogenous AHR agonist in 
preference to several other possible ligands such as TCDD. 
BαP is a polycyclic aromatic hydrocarbon and considered a 
potent activator of AHR (Matsunawa et al. 2009), which is 
what was required by this study and achieved as indicated 
by the successful activation of DRE-driven reporter activity 
and AHR target gene expression. Conversely, a more 
common agonist, TCDD, is incompletely metabolized by 
xenobiotic enzymes, which could lead to more off-target 
effects (Bohonowych & Denison 2007). Owing to the 
complex biology of AHR, different agonists may result in 
different AHR-driven activation pathways (Hockley et al. 
2007, Harper et al. 2013, Lowe et al. 2014) and therefore 
the use of any agonist has to be taken with adequate 
consideration regarding this fact.
In vitro studies using GH3 cells were used to study 
the functional role of the AHR in pituitary tumours. 
GH3 cells are of rat origin and are currently the most 
commonly used in vitro model of functional secreting 
tumours since they secrete both growth hormone and 
prolactin. GH3 cells possess functional AHR, although at 
low expression levels and do respond to both classical and 
novel agonists through increased expression of xenobiotic 
metabolic enzymes (Moran et al. 2012, Long et al. 2013, 
Lecoq  et  al. 2016). Proliferation analysis revealed the 
tumour suppressive ability of the AHR with increasing 
AHR expression resulting in a relative reduction in GH3 
cell proliferation. Silencing of endogenous Ahr similarly 
resulted in an increase in GH3 proliferation while the 
addition of exogenous ligand did not influence either 
scenario significantly indicating distinct roles of AHR as 
a xenobiotic receptor and as a regulator of proliferation.
Review of the literature supported a possible role of 
AHR on the cell cycle independent of its function as a 
xenobiotic receptor. Studies regarding the mechanism(s) 
by which AHR regulates cell proliferation demonstrated 
direct interaction with the retinoblastoma (Rb) protein 
in 5L hepatoma and MCF-7 breast carcinoma cells 
(Ge  &  Elferink 1998, Puga  et  al. 2000). The Rb protein 
in its hypophosphorylated state inhibits the G1/S 
transition by binding to and repressing E2F transcription 
factors, thus preventing the transition to the S phase 
(Dyson 1998). AHR binds to Rb and maintains it in its 
active hypophosphorylated state (Puga et al. 2000). AHR 
has also been reported to activate transcription of the 
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cyclin-dependent kinase inhibitor CDKN1B (p27) gene, a 
tumour suppressor that inhibits cyclin–cyclin-dependent 
kinase (CDK) interactions and maintains Rb in its 
hypophosphorylated state (Kolluri et al. 1999).
Our results demonstrate that AHR overexpression 
reduces cell proliferation and inhibits cell cycle 
progression in GH3 cells. Using co-immunoprecipitation, 
the physical interaction between Ahr and Rb in GH3 
cells was confirmed in accordance with other studies 
carried out in different cell contexts (Ge & Elferink 1998, 
Marlowe et al. 2004). Additionally, our results also indicate 
that AHR overexpression is able to increase expression of 
CDKIs, particularly p21, and reduce expression of cyclin 
E1, two important mediators of the cell cycle. Jackson and 
coworkers (Jackson  et  al. 2014) postulate that AHR can 
directly transactivate expression of the p21 gene through 
a non-consensus XRE. Therefore, we postulate that AHR, 
acting through its both or either of these two mechanisms, 
that is, the interaction with Rb and the ability to increase 
expression of CDKIs, is able to reduce E2F-driven cell cycle 
progression, an effect that is not altered by the presence 
of an exogenous agonist. In fact, addition of ligand 
appears to hinder AHR-mediated cell cycle inhibition, 
allowing the hypothesis that an activating ligand might 
sequester AHR towards its xenobiotic function and 
inhibit its ability to repress cell cycle progression. These 
results are in agreement with those reported by Moran 
and coworkers (Moran  et  al. 2012) in which GH3 cells 
treated with AHR ligand β-naphthoflavone failed to show 
any significant difference in proliferation or cell cycle 
progression, indicating that activation of xenobiotic AHR 
signalling alone does not alter pituitary cell proliferation. 
Notwithstanding, one can never exclude completely the 
presence of endogenous AHR ligands which, although 
are generally of low affinity, may still activate the AHR 
sufficiently (Opitz et al. 2011).
This study also further highlights the deregulation 
in cell cycle of PA and the role the AHR may play 
in regulating this balance in key cell cycle protein 
expression. The 31 PA analysed by qPCR exhibited altered 
CDK–CDKN expression with a general increase in cyclins 
and CDK gene expression and a reduction in CDKN 
expression in tumours as compared to normal controls 
(Fig. 4). Cyclin D1 and cyclin E protein expression were 
already reported to be increased in a PA when compared 
to normal controls in other studies (Jordan  et  al. 2000, 
Turner et al. 2000, Saeger et al. 2001, Dworakowska et al. 
2009, Formosa  et  al. 2012). Similarly, CDKN1B protein 
expression is also found to be significantly reduced in 
PA (Bamberger et al. 1999). In this study, CDKN1A (p21) 
expression has not been found to differ between tumour 
and control pituitary tissues although non-functional 
tumours appear to have significantly less p21 protein than 
GH-secreting tumours. p21 expression has been shown 
to play a significant role in inducing senescence and in 
regulating the anti-proliferative role of somatostatin 
analogues (Chesnokova et al. 2008, Monahan et al. 2012). 
The possibility that AHR induces relative changes in 
the simultaneous or sequential expression of different 
cell cycle regulatory proteins in order to regulate cell 
proliferation constitutes a valid hypothesis. According to 
Marlowe et al. (2004) both mechanisms, interaction with 
Rb and regulation of expression of CDKNs might play an 
equal and synergistic role in determining the cell cycle 
repression caused by AHR activity. Figure  6 summarizes 
how the AHR protein might be acting in pituitary cells, 
though these two pathways that might be directly or 
indirectly connected through feedback mechanisms.
This study aimed at identifying novel pathways that 
might regulate PA behaviour and is the first to identify a 
mechanistic role for the AHR in pituitary tumourigenesis. 
Figure 6
Illustration of AHR activity in pituitary cells. The AHR may act through 
two pathways in the pituitary cells which can either be distinct in activity 
or influence each other by sequestering AHR protein. Pathway 1 
illustrates the standard canonical xenobiotic signaling by AHR which is 
activated by exogenous or endogenous ligands to translocate to the 
nucleus together with ARNT and transcribe target genes such as CYP1A1, 
AHR among others. The second pathway involves the influence of AHR 
on cell cycle regulators. Through its interaction with Rb protein, AHR is 
able to maintain it in its hypo-phosphorylated state where it inhibits E2F 
activity and hence represses cell cycle progression. Alternatively, AHR may 
also increase expression of CDKN1A and CDKN1B genes resulting in 
increased p21 and p27 protein levels which also repress cyclin/CDK 
activity and maintain the hypo-phosphorylated state of Rb, thereby also 
reducing cell cycle progression.
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Recent studies into the homeostatic roles of this 
nuclear receptor have elucidated important functions 
involving cell differentiation, immunity regulation and 
determination of cell fate in blood cell lineages among 
others (Singh et al. 2009, Vogel et al. 2009, Platten et al. 
2014). Consequently, the AHR is being given increasing 
attention with regards to its role in normal cell biology 
above its function as a xenobiotic receptor. This study 
highlights the complexity of the AHR with its multiple 
functions in pituitary tissue, from xenobiotic signalling, 
to endocrine disruption to cell cycle regulation and PA 
behaviour. Given its close association with AIP, the 
discovery of AHR as a putative tumour suppressor may 
shed new light upon the importance of the AIP–AHR 
interaction in PA susceptibility. These proteins work in 
a complex network of interactions and cascading effects 
that are very difficult to elucidate in their entirety. 
Nonetheless, this study provides irrefutable evidence 
regarding the putative roles of AHR in the pituitary, which 
may as yet be revealed to be much more complex. With 
regards to cell proliferation, the corroboration of results 
from both in vivo specimens and in vitro analyses lend 
weight to the hypothesis that AHR may act as a tumour 
suppressor in PA.
Supplementary data
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